人工智慧如何实现医疗事务中更快、更明智的决策：专家问答

人工智慧正在改变医疗事务的决策，提供许多好处和机会。快速处理来自临床试验、真实世界证据 (RWE) 和科学文献的大型数据集。人工智慧可以帮助识别和吸引关键意见领袖，优化互动并确保有效沟通。

ChatGPT 等生成式 AI 工具正在改进与医疗专业人员 (HCP) 和患者沟通的书面和视觉内容的创作，从而提高效率和品质。这使得医疗事务部能够专注于策略任务。

主要问题

• 人工智慧是如何影响协和麒麟的医疗事务决策过程的？
• 人工智慧提升成果和效率的领域范例
• 将人工智慧驱动的洞察融入策略决策的最大课题
• 在您的工作中，AI 如何增强临床试验数据和 RWE 的分析？
• 如何确保 AI 产生内容的品质和准确性？
• 特定的人工智慧驱动项目已改善了患者的治疗效果
• 将人工智慧引入医疗事务时需要考虑哪些伦理问题？
• 如何解决人工智慧应用中的资料隐私和安全问题？
• 预见人工智慧在医疗事务中的应用会出现哪些趋势？
• 协和麒麟及其医疗事务部门如何为製药业的下一波人工智慧创新做好准备

该报告是基于专有产业研究和对产业思想领袖的深入访谈而得出的独立而简洁的分析。该报告对製药业高管需要了解的关键趋势和市场发展进行了深入分析，以应对未来的机会和课题。每份报告的重点都是透过对二手文献的回顾和已确定的知识差距来确定的。基于这项初步研究，我们将制定基于证据、专家指导的讨论指南，以确保研究回答最重要的问题。此外，我们有严格的筛选标准，以确保受访者拥有谈论该主题所需的适当经验、知识和地位。

作为专注于製药领域的值得信赖的行业领导者，本报告为生物製药专业人士和决策者提供了深入、可行的见解。我们深厚的行业知识使我们能够提供相关且有价值的见解，帮助我们的客户了解新兴趋势并有效地解决复杂的课题。我们的报告以广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解为后盾，为您提供所需的准确性和可信度。独家采访和数据以及持续的市场监控使我们能够全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包含 KOL 洞察和定量医生调查的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策并在快速变化的行业中保持竞争力。

Transforming decision-making in medical affairs, AI offers numerous benefits and opportunities. Along with rapidly processing large data sets from clinical trials, real-world evidence (RWE) and scientific literature. It helps to identify and engage with key opinion leaders, optimising interactions and ensuring effective dissemination of information.

Generative AI tools like ChatGPT are improving the creation of written and visual content for communication with healthcare professionals (HCPs) and patients, enhancing both efficiency and quality. This allows medical affairs to focus on strategic tasks.

FirstWord spoke with Olivia Kager, medical lead for Kyowa Kirin's German, Austrian and Swiss territories, about how AI is impacting decision-making within the company's medical affairs functions.

Key Questions Answered:

• In what ways has AI started to impact decision-making processes in medical affairs at Kyowa Kirin?
• Can you share examples of areas where AI has improved outcomes or efficiencies?
• What are the biggest challenges in integrating AI-driven insights into strategic decision-making?
• How does AI enhance the analysis of clinical trial data and RWE in your role?
• How do you ensure the quality and accuracy of AI-generated content?
• Can you discuss any specific AI-driven projects that have led to better patient outcomes?
• What ethical considerations do you take into account when implementing AI in medical affairs?
• How do you address concerns about data privacy and security in AI applications?
• What future trends do you foresee in the use of AI in medical affairs?
• How is Kyowa Kirin and its medical affairs function preparing for the next wave of AI innovations in pharma?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.